Modified_Glasgow_Prognostic_Score v.1
The modified glasgow prognostic score provides improved cancer prognosis over the original score, based on serum biomarkers.
Provides improved cancer prognosis over the original score, based on serum biomarkers.
Use in patients with known cancer. Why use: Multiple studies suggest significantly worse outcome in multiple types of cancer, including “increased weight loss, poor performance status, increased comorbidity, increased pro-inflammatory and angiogenic cytokines and complications on treatment.” (McMillan DC 2013)
The Modified Glasgow Prognostic Score (mGPS) has been evaluated across numerous different cancer cohorts and suggests incrementally worsening prognosis with increasing score. Depending upon patient selection, stage, cancer and other factors the resulting survival numbers vary widely. The modified GPS uses the same parameters as the original GPS (CRP and albumin), but weighs the inflammatory component more heavily; i.e., patients with low albumin are still assigned a score of 0 even if CRP is elevated. This modification was shown to have better correlation with survival (in colon and rectal cancer from the original paper, and in other cancers from the validation papers).
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104(4):726–734 Validation Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg 2011;201(2):186–191 Tai CG, Johnson TV, Abbasi A, et al. External validation of the modified Glasgow prognostic score for renal cancer. Indian Journal of Urology : IJU : Journal of the Urological Society of India. 2014;30(1):33-37. doi:10.4103/0970-1591.124203. Simmons CP, et al. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.Lung Cancer. 2015 Jun;88(3):304-9. doi: 10.1016/j.lungcan.2015.03.020. Epub 2015 Mar 28.
openEHR-EHR-OBSERVATION.modified_glasgow_prognostic_score, openEHR-EHR-EVALUATION.modified_glasgow_prognostic_score
